Dynamic Changes in Estrogen Receptor Alpha (ERα) Promoter Methylation and Drug Resistance in Breast Cancer Cells Background Breast cancer is one of the most common cancers among women worldwide, with approximately 75% of breast cancer patients expressing estrogen receptor alpha (ERα, gene symbol ESR1). ERα is not only an important prognostic marker...
Revumenib Alters the Treatment Landscape for KMT2A-Rearranged Leukemia Academic Background Leukemia is a malignant disease caused by abnormalities in the hematopoietic system, with KMT2A-rearranged (KMT2A-r) leukemia being a common subtype, particularly in pediatric and adult acute myeloid leukemia (AML). Rearrangements of the KMT2A gene (lysine me...
Academic Background and Problem Statement In recent years, immune checkpoint inhibitors (ICIs) have made significant progress in cancer treatment, particularly anti-PD-1 and anti-PD-L1 antibodies, which have become the standard of care for first-line treatment in various cancers. However, despite the notable clinical activity of these therapies in ...
The Expression of High-Dimensional Mapping of Human CEACAM1 on Immune Cells and Its Association with Melanoma Drug Resistance Research Background Human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) is an inhibitory cell surface protein that acts through homophilic and heterophilic ligand binding. The expression of this protein...
Engineering Selective Gene Drives to Steer Tumor Evolution to Counteract Drug Resistance As tumors evolve, targeted therapies against cancer often fail due to the evolution of drug resistance. This study demonstrates a way to manipulate tumor evolution repeatedly to design therapeutic opportunities, even in the presence of genetic heterogeneity. We...
The Antitumor Effect of Dual Inhibition of NAMPT and PAK4 in a 3D Spheroid Model of Platinum-Resistant Ovarian Cancer Platinum-resistant ovarian cancer is a malignant gynecological tumor that is difficult to treat and has a short patient survival period. In recent years, researchers have sought new treatment strategies, targeting cancer stem cells ...
Analysis of Intratumor Heterogeneity in Liver Cancer Using Pharmacogenomics: A Study Based on a Large-Scale Organoid Biobank Academic Background Primary liver cancer (PLC) is the third leading cause of cancer-related deaths worldwide, mainly comprising hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and a mixed form called co...